Sanofi

Thrombogenics Nv

Claudia Fromond

Daniel J Tavares

Fabienne Parker

Jiawen Han

Min Li

Xiao-Mai Zhou

Alain Commercon

Herve Bouchard

Marie-Christine Bissery

Vincent Mikol

Hervé Bouchard

Michel Streuli

Chonghui Zhang

Veronique Blanc

Ingrid Sassoon

Patricia Vrignaud

Richard Reinier Zwaal

Hoa Thu Ngo

Sofie Notebaert

Véronique Blanc

Min Immunogen Inc Li

Antagonistic antibodies that specifically bind to and inhibit Class A Eph receptors are provided. Also provided are cytotoxic conjugates, pharmaceutical compositions and kits comprising these antibodies.

EPHA2 receptor antagonist antibodies

The invention relates to antibodies binding to the PDGF-C antigen and capable of inhibiting binding of PDGF-C to the PDGFR&#x3b1; receptor and of inhibiting PDGFR&#x3b1; activation by PDGF-C. Applications of such antibodies are also disclosed. These include treatment of cancer.

Anti-PDGF-C antibodies

The present disclosure relates to an antibody or an epitope-binding fragment thereof that specifically binds to an EphA2 receptor. It further relates to a conjugate comprising a cytotoxic agent which is covalently bound to the antibody and a method for preparing such a conjugate.

Antibodies that specifically bind to the EphA2 receptor

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the A class of Eph receptors.

Methods of use for antibodies that specifically bind to the EphA2 receptor

Growing community of inventors

Fleury en Biere, France

Claudia Fromond